Vessey to leave BMS in July

EVP of Research and Early Development Rupert Vessey will leave Bristol Myers Squibb Co. (NYSE:BMY) on July 3, according to an SEC filing. Vessey joined BMS in 2019, before which he was president of research and early development at Celgene Corp.

Gene therapy company enGene Inc. hired Alex Nichols as president and COO. Nichols was president and CEO of Mythic Therapeutics Inc., an antibody-drug conjugate (ADC) company he also co-founded. ...